Reiko Namikawa
Director/Board Member at TMS CO., LTD.
Reiko Namikawa active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TMS CO., LTD. | Director/Board Member | 2021-04-30 | - |
| Independent Dir/Board Member | 2021-04-30 | - | |
REGiMMUNE Corp.
 REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Corporate Officer/Principal | 2022-05-31 | - |
| Chief Tech/Sci/R&D Officer | 2007-02-28 | 2022-05-31 | |
Mitsui & Co. Global Investment, Inc.
 Mitsui & Co. Global Investment, Inc. Investment ManagersFinance Mitsui & Co. Global Investment, Inc. (Mitsui & Co. Global Investment) is a venture capital subsidiary of Mitsui Ventures founded in 1999. The firm is headquartered in Menlo Park, California. | Private Equity Investor | - | - |
Career history of Reiko Namikawa
Former positions of Reiko Namikawa
| Companies | Position | Start | End |
|---|---|---|---|
NapaJen Pharma, Inc.
 NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Director/Board Member | - | - |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Director/Board Member | 2017-11-22 | - |
| ProtElix, Inc. | Corporate Officer/Principal | - | - |
Bio Genomics, Inc.
 Bio Genomics, Inc. Bio Genomics, Inc. produces and supplies laboratory animals such as mice, rats, guinea pigs, rabbits, and beagles. The company is based in Seoul, South Korea. | Corporate Officer/Principal | - | - |
| GeneTrol Biotherapeutics, Inc. | Corporate Officer/Principal | - | - |
| DNAX Research, Inc. | Corporate Officer/Principal | - | - |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Reiko Namikawa
| Nagoya University | Doctorate Degree |
Statistics
International
| United States | 9 |
| Japan | 4 |
| South Korea | 2 |
Operational
| Corporate Officer/Principal | 8 |
| Director/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 5 |
| Health Services | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| TMS CO., LTD. | Commercial Services |
| Private companies | 11 |
|---|---|
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
Abmaxis, Inc.
 Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Health Technology |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
| Clearview Projects, Inc. | |
| DNAX Research, Inc. | |
| GeneTrol Biotherapeutics, Inc. | |
| ProtElix, Inc. | |
Bio Genomics, Inc.
Bio Genomics, Inc. Bio Genomics, Inc. produces and supplies laboratory animals such as mice, rats, guinea pigs, rabbits, and beagles. The company is based in Seoul, South Korea. | |
NapaJen Pharma, Inc.
NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Health Technology |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
Mitsui & Co. Global Investment, Inc.
Mitsui & Co. Global Investment, Inc. Investment ManagersFinance Mitsui & Co. Global Investment, Inc. (Mitsui & Co. Global Investment) is a venture capital subsidiary of Mitsui Ventures founded in 1999. The firm is headquartered in Menlo Park, California. | Finance |
- Stock Market
- Insiders
- Reiko Namikawa
- Experience
